Summary of Ovid Therapeutics Inc.

Company Overview:
Ovid Therapeutics Inc. is a biotechnology company focused on developing therapeutics for neurological disorders. It is incorporated in Delaware and is publicly traded on Nasdaq under the symbol OVID.

Core Business:

• Specializes in research and development of medicines targeting rare neurological disorders, including epilepsy, neurodevelopmental conditions, and other neurogenetic diseases.
• The company's strategy includes leveraging its expertise in neuroscience to discover and commercialize innovative therapies.

Key Details from the 10-K/A Filing:

• Number of Employees: The company has approximately 71.1 million shares of common stock outstanding as of April 24, 2025. The number of employees is not directly specified in the document.
• Customer Base: No specific details on the number of customers or clients are provided.
• Revenue and Income: This amended filing explicitly states that it does not include or update any financial statements or disclosures regarding revenue, net income, or overall financial performance. Therefore, exact revenue or income figures are not provided in the document.

Additional Corporate Information:

• Market Capitalization: As of June 30, 2024, the company’s market value held by non-affiliates was approximately $45.9 million.
• Principal Offices: Located at 441 Ninth Avenue, 14th Floor, New York, NY 10001.
• Regulatory Status: Large accelerated filer and smaller reporting company under SEC rules, with filings required under SEC's reporting standards.

Management and Governance:

• The company’s executive leadership includes a Chairman and CEO, Jeremy M. Levin, DPhil.
• The Board of Directors comprises experienced professionals from the biotech, finance, and healthcare sectors.
• The company maintains robust governance policies, including a code of conduct, insider trading policies, and independent director standards.

Financial Disclosures:

• No detailed financial data (revenues, profits, losses) are included in this amended filing, which primarily focuses on regulatory and governance disclosures as required for an annual report on Form 10-K/A.